Overview

Olaparib Maintenance Treatment Versus Placebo in Patients With PSR Ovarian Cancer Who Are in CR or PR to Platinum-based Chemotherapy and Whose Tumours Carry sBRCAm or HRR-associated Genes Mutations

Status:
Withdrawn

Trial end date:
2019-06-01

Target enrollment:

Participant gender:

Summary

Olaparib administered as monotherapy in the maintenance setting improves progression free survival compared to placebo in patients whose tumours carry loss of function (deleterious or suspected deleterious) somatic BRCA mutations or loss of function (deleterious or suspected deleterious) mutation in non-BRCA Homologous Recombination Repair (HRR) -associated genes who have a complete or partial response to platinum-based chemotherapy.

Phase:

Phase 3

Details

Lead Sponsor:

AstraZeneca

Collaborator:

Myriad Genetic Laboratories, Inc.

Treatments:

Olaparib